Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 7
Submit an article Journal homepage
644
Views
98
CrossRef citations to date
0
Altmetric
Review

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications

Sho-ichi Yamagishi Kurume University School of Medicine, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume, 67 Asahi-machi, Kurume 830-0011, Japan +81 942 31 7873; +81 942 31 7873; [email protected]
,
Kazuo Nakamura Kurume University School of Medicine, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume, 67 Asahi-machi, Kurume 830-0011, Japan +81 942 31 7873; +81 942 31 7873; [email protected]
,
Takanori Matsui Kurume University School of Medicine, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume, 67 Asahi-machi, Kurume 830-0011, Japan +81 942 31 7873; +81 942 31 7873; [email protected]
,
Seiji Ueda Kurume University School of Medicine, Department of Medicine, Division of Nephrology, Kurume, Japan
,
Kei Fukami Kurume University School of Medicine, Department of Medicine, Division of Nephrology, Kurume, Japan
&
Seiya Okuda Kurume University School of Medicine, Department of Medicine, Division of Nephrology, Kurume, Japan
Pages 983-996 | Published online: 12 Jun 2008

Bibliography

  • Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999;48:937-42
  • Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20
  • Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005;11:2279-99
  • The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9
  • Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-67
  • Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
  • Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-21
  • Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654-60
  • Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003;419:63-79
  • Yamagishi S, Takeuchi M, Inagaki Y, et al. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmcol Res 2003;23:129-34
  • Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101
  • Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600
  • Wendt T, Bucciarelli L, Qu W, et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002;4:228-37
  • Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000;2:430-6
  • Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann NY Acad Sci 1997;811:115-27
  • Takenaka K, Yamagishi S, Matsui T, et al. Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 2006;3:73-7
  • Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3:382-90
  • Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-8
  • Bucala R, Mitchell R, Arnold K, et al. Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor. J Biol Chem 1995;270:10828-32
  • Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272:17810-4
  • Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96:1395-403
  • Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995;1:447-56
  • Bierhaus A, Illmer T, Kasper M, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997;96:2262-71
  • Tanaka N, Yonekura H, Yamagishi S, et al. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-90
  • Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;43:1649-56
  • Niwa T, Katsuzaki T, Miyazaki S, et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997;99:1272-80
  • Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999;10:822-32
  • Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003;108:1070-7
  • Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959-72
  • Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-37
  • Guo J, Ananthakrishnan R, Qu W, et al. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 2008;19:961-72
  • Myint KM, Yamamoto Y, Doi T, et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006;55:2510-22
  • Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-8
  • Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 2000;60:55-65
  • Brownlee M, Vlassara H, Kooney A, et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-32
  • Hoang A, Murphy AJ, Coughlan MT, et al. Advanced glycation of apolipoprotein A-1 impairs its anti-atherogenic properties. Diabetologia 2007;50:1170-9
  • Picard S, Parthasarathy S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1992;89:6876-80
  • Bucala, Makita Z, Vega G, et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441-5
  • Huijberts MS, Wolffenbuttel BH, Boudier HA, et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993;92:1407-11
  • Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 1996;93:1905-12
  • Chang KC, Tseng CD, Wu MS, et al. Aminoguanidine prevents arterial stiffening in a new rat model type 2 diabetes. Eur J Clin Invest 2006;36:528-35
  • Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813-23
  • Panagiotopoulos S, O'Brien RC, Bucala R, et al. Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. Atherosclerosis 1998;136:125-31
  • Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40
  • Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003;419:31-40
  • Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000;275:21177-84
  • Price DL, Rhett PM, Thorpe SR, Baynes JW. Chelating activity of advance glycation end-product inhibitors. J Biol Chem 2001;276:48967-72
  • Voziyan PA, Metz TO, Baynes JW, Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002;277:3397-403
  • Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005;62:1671-81
  • Giannoukakis N. Pyridoxamine. Curr Opin Investig Drugs 2005;6:410-8
  • Shimoi K, Okitsu A, Green MH, et al. Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. Mutat Res 2001;480-481:371-8
  • Endo N, Nishiyama K, Okabe M, et al. Vitamine B6 suppresses apoptosis of NM-1 bovine endothelial cells induced by homocysteine aand copper. Biochim Biophys Acta 2007;1770:571-7
  • Alderson NL, Chachich MN, Youssef NN, et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003;63:2123-3
  • Nakamura S, Li H, Adijiang A, et al. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 2007;22:2165-74
  • Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9
  • Ruggiero-Lopez D, Lecomte M, Moinet G, et al. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999;58:1765-73
  • Rahbar S, Natarajan R, Yerneni K, et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000;301:65-77
  • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
  • Ouslimani N, Mahrouf M, Peynet J, et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 2007;56:308-13
  • Brown BE, Mahroof FM, Cook NL, et al. Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Diabetologia 2006;49:775-83
  • Regan TJ, Jyothirmayi GN, Laharm C, Jain A. Left ventricular diastolic dysfunction in diabetic or hypertensive subjects: role of collagen alterations. Adv Exp Med Biol 2001;498:127-32
  • Beisswenger P. Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetic Metab 2003;29:6S95-103
  • Figarola JL, Scott S, Loera S, et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 2003;46:1140-52
  • Bhatwadekar A, Glenn JV, Figarola JL, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol 2008;92:545-7
  • Vasan S, Zhang X, Zhang X, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275-8
  • Wolffenbuttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998;95:4630-4
  • Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products. Sparking the development of diabetic vascular injury. Circulation 2006;114:597-605
  • Usta MF, Kendiric M, Gur S, et al. Breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin-induced diabetic rats; preventive versus curative treatment. J Sex Med 2006;3:242-50
  • Demiot C, Fromy B, Saumet JL, Sigaudo-Roussel D. Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice. Cardiovasc Res 2006;69:245-52
  • Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Cir Res 2003;92:785-92
  • Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001;104:1464-70
  • Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007;25:577-83
  • Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005;11:191-5
  • Available from: www.clinicaltrials.gov
  • Fan X, Monnier VM. Nucleophilic compounds decrease crystallin ascorbylation in the hSVCT2 mouse model of lenticular aging. Invest Ophthalmol Vis Sci 2008; In press
  • Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998;4:1025-31
  • Bucciarelli L, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002;106:2827-35
  • Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46:2916-24
  • Kaji Y, Usui T, Ishida S, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007;48:858-65
  • Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease. The next C-reactive protein? Arterioscler Thromb Vasc Biol 2005;25:879-82
  • Challier M, Jacqueminet S, Benabdesselam O, et al. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 2005;51:1749-50
  • Nakamura K, Yamagishi S, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007;23:368-71
  • Tan KC, Shiu SW, Chow WS, et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006;49:2756-62
  • Nakamura K, Yamagishi S, Matsui T, et al. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med 2007;7:188-90
  • Yamagishi S, Adachi H, Nakamura K, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006;55:1227-31
  • Nakamura K, Yamagishi S, Adachi H, et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007;13:185-9
  • Nakamura K, Yamagishi S, Adachi H, et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008;24:109-14
  • Yamagishi S, Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 2007;27:e32
  • Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets 2007;8:1138-43
  • Miura J, Yamamoto Y, Osawa M, et al. Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 2007;27:253-4
  • Katakami N, Matsuhisa M, Kaneto H, et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005;28:2716-21
  • Sakurai S, Yamamoto Y, Tamei H, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006;73:158-65
  • Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587-93
  • Humpert PM, Djuric Z, Kopf S, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007;6:9
  • Basta G, Sironi AM, Lazzerini G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006;91:4628-34
  • Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005;16:2363-72
  • Nakamura K, Yamagishi S, Nakamura Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005;70:137-41
  • Yamagishi S, Takeuchi M, Matsui T, et al. Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett 2005;579:4265-70
  • Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol 2004;75:1062-9
  • Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999;96:10836-41
  • Matsumoto Y, Takahashi M, Ogata M. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Jpn J Ophthalmol 2002;46:406-12
  • Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003;52:2586-93
  • Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006;69:73-80
  • De Vriese AS, Tilton RG, Elger M, et al. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001;12:993-1000
  • Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, et al. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002;51:3090-4
  • Yamagishi S, Nakamura K, Takenaka K, et al. Pleiotropic effects of nifedipine on atherosclerosis. Curr Pharm Des 2006;12:1543-7
  • Celletti FL, Waugh JM, Amabile PG, et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9
  • Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-γ (PPAR-γ)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007;7:463-9
  • Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor antagonist, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-γ activation. J Int Med Res 2007;35:482-9
  • Yoshida T, Yamagishi S, Nakamura K, et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006;49:3094-9
  • Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2008;75:130-4
  • Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen. Ophthalmic Res 2008;40:10-5
  • Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-84
  • Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypothese 2005;64:476-8
  • Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004;53:2662-8
  • Miyata T, van Ypersele de Strihou C, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002;13:2478-87
  • Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-82
  • Sebekova K, Schinzel R, Munch G, et al. Advanced glycation end-product levels in subtotally nephrectomized rats: beneficial effects of angiotensin II receptor 1 antagonist losartan. Miner Electrolyte Metab 1999;25:380-3
  • Fan Q, Liao J, Kobayashi M, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004;19:3012-20
  • Yamagishi S, Takeuchi M, Inoue H. Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats. Drugs Exp Clin Res 2005;31:45-51
  • Sebekova K, Gazdikova K, Syrova D, et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003;17:265-70
  • Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Prac 2006;74:201-3
  • Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res 2004;30:169-75
  • Matsui T, Yamagishi S, Nakamura K, et al. Nifedipine, a calcium-channel blocker, inhibits advanced glycation end-product-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells. J Int Med Res 2007;35:107-12
  • Yamagishi S, Inagaki Y, Kikuchi S. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res 2003;29:147-52
  • Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004;19:2505-12
  • Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003;4:628-36
  • Abe R, Fujita Y, Yamagishi S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem 2007;7:649-61
  • Yamagishi S, Inagaki Y, Amano S, et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun 2002;296:877-82
  • Inagaki Y, Yamagishi S, Okamoto T, et al. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003;46:284-7
  • Yamagishi S, Amano S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res 2003;65:186-90
  • Yamagishi S, Inagaki Y, Nakamura K, et al. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004;37:497-506
  • Yamagishi S, Nakamura K, Ueda S, et al. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res 2005;320:437-45
  • Yamagishi S, Matsui T, Nakamura K, et al. Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 2006;71:222-6
  • Yamagishi S, Ueda S, Matsui T, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 2007;14:832-5
  • Yamagishi S, Matsui T, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res 2006;72:86-90
  • Yamagishi S, Matsui T, Nakamura K, et al. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res 2007;39:92-7
  • Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006;281:20213-20
  • Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006;37:1-12
  • Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Opthalmology 2006;113:294-301
  • Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2002;50:2641-5
  • Boehm BO, Lang G, Volpert O, et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 2003;46:394-400
  • Yokoi M, Yamagishi S, Takeuchi M, et al. Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy. Br J Ophthalmol 2005;89:673-5
  • Yokoi M, Yamagishi S, Saito A, et al. Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2007;91:885-7
  • Yoshida Y, Yamagishi S, Matsui T, et al. Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy. Br J Ophthalmol 2007;91:1133-4
  • Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002;16:1928-30
  • Okamoto T, Yamagishi S, Inagaki Y, et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun 2002;297:419-24
  • Yoshida T, Yamagishi S, Nakamura K, et al. Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing reactive oxygen species generation. Vasc Dis Prev 2007;4:213-6
  • Yamagishi S, Matsui T, Nakamura K, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 2005;27:189-95
  • Yamagishi S, Nakamura K, Matsui T, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med Hypotheses 2006;66:273-5
  • Yamagishi S, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004;165:1865-74
  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPS 33). Lancet 1998;352:837-53

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.